United States Peptide Cancer Vaccine Market Size Analysis, Growth Trends & Forecast to 2034

United States Peptide Cancer Vaccine Market Overview 

The United States peptide cancer vaccine market is projected to expand from USD 2.44 billion in 2026 to USD 14.58 billion by 2034, registering a CAGR of 26.4% during 2026–2034. The peptide cancer vaccine market in the United States represents a nascent segment of the cancer immunotherapy market due to the increased interest in therapeutics that induce targeted immunity against tumor-associated antigens and mutations. The market comprises both multi-antigen peptide cancer vaccines and individualized neoantigen cancer vaccines, with more emphasis on the development of cancer vaccines against tumors like melanoma, pancreatic cancer, breast cancer, glioblastoma, and hematological cancers. Competitiveness in the market is mainly pipeline-oriented, with companies trying to differentiate themselves based on their ability to select antigens, peptides, immune-stimulating techniques, biomarkers for patient selection, and combination therapies with immune-checkpoint inhibitors.

United States Peptide Cancer Vaccine Market Growth Drivers

Increasing Clinical Validation of Peptide-Based Cancer Vaccines

Growing clinical evidence is building confidence in the use of peptides for cancer vaccines as a form of targeted immunotherapy, especially in those tumors with specific molecular targets. According to Nature Medicine (January 9, 2024), AMPLIFY-201, a Phase I trial of ELI-002 2P, a lymph node-targeted peptide vaccine against mutant KRAS in patients with pancreatic and colorectal cancer, exhibited evidence of mutant KRAS-specific T-cell responses and biomarker responses from the tumor, suggesting early evidence of a targeted immune response to mutant KRAS from peptide vaccination. This was further validated by the results of the final AMPLIFY-201, released in Nature Medicine (August, 2025), which exhibited sustained immune responses and a link between higher levels of T-cell responses and relapse-related outcomes. More recently, according to Annals of Oncology (April 21, 2026), the Phase III trial of IO102-IO103 combined with pembrolizumab resulted in better progression-free survival compared to pembrolizumab alone, even though the predefined level of statistical significance was not reached in the treatment of advanced melanoma.

Rising Focus on Tumor-Specific and Personalized Immunotherapy

The rising interest in precision medicine has led to an increased interest in developing personalized cancer vaccines that will target only the neoantigens that are specific to the individual rather than those that are ubiquitously expressed antigens in all patients. As seen in the Nature Medicine publication dated April 2024, a phase I/II clinical trial of a personalized neoantigen vaccine in combination with pembrolizumab in advanced hepatocellular carcinoma showed that the vaccine was able to induce T-cell responses that were specific for the neoantigens, with the responses being correlated with the number of neoantigens in the vaccine. Likewise, in the study published in Nature dated November 13, 2024, the same research showed that a personalized neoantigen vaccine induced T-cell responses against multiple cancer driver mutations in patients with high-risk renal cell carcinoma, showing that individualized vaccines have the potential to target individualized patient tumor biology. These findings have increased interest in genomic profiling, neoantigen discovery, personalized peptides, and personalized vaccine development to develop peptide cancer vaccines in the US.

United States Peptide Cancer Vaccine Market Restraint

Long Development Timelines and High Clinical Risk

The development of peptide-based cancer vaccines is characterized by long development times and high levels of clinical uncertainty due to the inability to prove that the presence of an immune reaction guarantees improved tumor control and clinical outcome. The development process involves numerous steps, including preclinical studies, multiple phases of clinical trials, patient recruitment, and assessment of safety and efficacy, as well as tumor biology and immune response variability that may affect clinical performance. All these aspects make the development process costly and risky for investors, thus slowing the development of peptide cancer vaccine programs.

United States Peptide Cancer Vaccine Market Opportunities

Expansion of Personalized Neoantigen Peptide Vaccines

The increasing trend towards personalized neoantigen peptide vaccines is one of the key opportunities in the U.S. peptide cancer vaccine market. With the advent of technological breakthroughs in tumor sequencing and bioinformatics, it is now possible to design vaccines using mutations specific to individual patients' tumors. This will allow improving the specificity of the immune response against a tumor and reducing dependence on shared cancer antigens. The trend is gaining popularity in the U.S.; thus, a clinical trial conducted at Mayo Clinic (NCT05269381) is examining the safety and efficacy of a personalized neoantigen peptide vaccine alone and combined with pembrolizumab in advanced solid tumors, while another one conducted at Fred Hutchinson Cancer Center (NCT05098210) is studying a personalized multi-peptide neoantigen vaccine in melanoma, breast cancer, and non-small cell lung cancer. Moreover, the FDA's Oncology Center of Excellence is citing personalized neoantigen-based approaches as an area of active science. As clinical validation continues to progress, opportunities are arising for players in tumor sequencing, neoantigen prediction, peptide synthesis, personalized vaccine production, immune monitoring, and combination with checkpoint inhibitors, among others.

Combination of Peptide Vaccines with Immune Checkpoint Inhibitors

The use of peptide cancer vaccines together with immune checkpoint inhibitors (ICIs) can be considered a promising opportunity in the U.S. peptide cancer vaccine market because the peptides can induce an immune response toward specific tumors, while checkpoint inhibitors would help to boost the functioning of those immune cells by preventing their inactivation via pathways such as PD-1/PD-L1. According to the results of a Phase III trial published in July 2026 in the Annals of Oncology, treatment of 407 patients with advanced melanoma who had no previous therapy with the peptide vaccine IO102-IO103 in combination with pembrolizumab achieved a median progression-free survival of 19.4 months versus 11.0 months for pembrolizumab monotherapy despite the lack of statistical significance at predefined levels. In addition, according to data published in 2025 on long-term follow-up of the MM1636 trial, IO102/IO103 in combination with nivolumab has demonstrated a 25.5-month median progression-free survival for metastatic melanoma patients. Thus, there are good prospects for U.S. companies to develop combination therapies, patient selection based on biomarkers, individualized peptides, and next-generation peptide platforms to be used in combination with ICIs.

United States Peptide Cancer Vaccine Market Scope

United States Peptide Cancer Vaccine Market Report Segmentation Analysis

The Personalized Peptide Vaccine Segment Is Expected to Dominate the United States Peptide Cancer Vaccine Market During the Forecast Period

The personalized peptide vaccines segment is anticipated to retain its lead position in the U.S. peptide cancer vaccines market through the forecast period owing to rising research in developing customized vaccines based on specific neoantigens and individual patient profiles. According to the information shared in the Asia-Pacific Journal of Clinical Oncology in August 2025, an assessment of 78 personalized cancer vaccine clinical trials showed that peptide vaccines make up 40% of total trials conducted and were the most prevalent vaccine types among the pipeline under review, whereas the U.S. represented 44% of total studies, indicating high-level development activity in the country. Some of the ongoing trials in the U.S. pipeline include the Phase I trial of a personalized multi-peptide neoantigen vaccine being conducted at the Fred Hutchinson Cancer Center, NCT05098210, involving testing of the drug along with nivolumab in patients with melanoma, metastatic breast cancer, and non-small cell lung cancer. Similarly, another ongoing trial, NCT05269381 at the Mayo Clinic, evaluates a personalized neoantigen peptide vaccine alongside pembrolizumab for advanced solid tumors. Such trends would drive segment growth owing to a rising clinical pipeline and demand for tumor sequencing and neoantigen identification, as well as manufacturing opportunities for personalized peptides.  

Melanoma Segment Is Expected to Dominate the United States Peptide Cancer Vaccine Market During the Forecast Period

The melanoma market segment is projected to account for the largest share of the U.S. peptide cancer vaccine market, driven by the relatively advanced stage of clinical development of peptide cancer vaccines for melanoma, as well as their extensive use in conjunction with immune checkpoint inhibitors. According to the results of a Phase III study in which 407 patients with untreated advanced melanoma were treated with a peptide cancer vaccine combination of IO102-IO103 plus pembrolizumab, the median progression-free survival was 19.4 months versus 11.0 months with pembrolizumab alone. These results just failed to reach the prespecified level of statistical significance. According to data provided by Nature Communications in December 2025, five years of follow-up on the results of the MM1636 study of the IO102-IO103 peptide vaccine in combination with nivolumab in advanced melanoma found a median progression-free survival of 25.5 months, which further confirms the need to study peptide vaccines for this indication. At the same time, there are ongoing United States clinical studies for personalized neoantigen peptide vaccines in the indication of melanoma, including the current NCI-listed study conducted by Fred Hutch/University of Washington for patients with stages IIIC–IV of melanoma. This suggests that, at the moment, melanoma can be considered one of the most developed application areas for peptide cancer vaccines in the United States, which will determine its market share over the forecast period.

Hospitals Segment Is Expected to Dominate the United States Peptide Cancer Vaccine Market During the Forecast Period

The hospitals segment is likely to lead the United States peptide cancer vaccine market during the forecast period, owing to the infrastructure provided by hospitals and comprehensive cancer centers that helps in selecting patients, tumor sequencing, developing personalized vaccines, and administering the vaccines, and monitoring the immune response in patients. As reported by the National Cancer Institute (NCI) in 2026, clinical trials of neoantigen and personalized peptide cancer vaccines in the United States are being carried out at major hospital-based cancer centers such as Mayo Clinic, Fred Hutchinson/University of Washington, Siteman Cancer Center, and Johns Hopkins/Sidney Kimmel Cancer Center. For instance, the PNeoVCA Phase I/II trial is currently being conducted at Mayo Clinic, Florida, to test a personalized neoantigen peptide vaccine alone and in combination with pembrolizumab for advanced solid tumors, while a Phase I trial being conducted at Siteman Cancer Center is testing a personalized synthetic long-peptide vaccine that utilizes the mutations found through tumor genomics testing. Clinical trials of peptide vaccines being carried out in hospital-based cancer centers help reinforce their lead as the prominent setting for vaccine administration, conducting clinical trials, carrying out molecular testing, monitoring patients, and providing multidisciplinary oncology treatment. 

The following segments are part of an in-depth analysis of the United States Peptide Cancer Vaccine Market:

United States Peptide Cancer Vaccine Market Competition Landscape Analysis

The United States market for peptide-based cancer vaccines features high levels of clinical development intensity, technology differentiation, and market fragmentation, with companies competing through technological advancements in areas such as peptide design, antigen targeting, personalization, neoantigen-based vaccines, vaccine delivery technologies, and immune system stimulation. Competitive positioning is determined by the maturity and quality of the clinical pipeline, indication, and ability to show safety and efficacy, as well as regulatory clearance and commercialization. In addition, competitors differentiate themselves by means of personalizing their products compared to off-the-shelf vaccines, combining peptides with immune checkpoint inhibitors, and selecting patients based on biomarkers, as well as technologies aimed at enhancing antigen presentation and T-cell activation.

United States Peptide Cancer Vaccine Market Recent Developments News:

• In March 2025, Mount Sinai reported promising Phase I results for PGV001, a personalized multi-peptide neoantigen cancer vaccine, in patients with different cancer types. The study demonstrated the feasibility of developing individualized vaccines based on mutations identified in each patient’s tumor, supporting continued development of personalized peptide vaccines in cancer treatment.

• In April 2025, Cancer Today reported growing clinical interest in therapeutic cancer vaccines, highlighting early-stage studies of peptide-based vaccines designed to target specific tumor mutations, including KRAS mutations. The developments reflect increasing research into peptide vaccines as a targeted immunotherapy approach and their potential use alongside existing cancer treatments.

• In January 2023, Evaxion announced that the U.S. FDA had granted Fast Track designation to EVX-01, its personalized peptide-based cancer immunotherapy candidate for metastatic melanoma. The candidate was developed using Evaxion’s AI-driven platform to identify patient-specific cancer targets and was being evaluated in combination with pembrolizumab, highlighting the growing integration of personalized peptide vaccine approaches with immune checkpoint inhibitors.  

The United States Peptide Cancer Vaccine Market is dominated by a few large companies, such as

• PDS Biotechnology Corporation

• SELLAS Life Sciences Group, Inc.

• Greenwich LifeSciences, Inc.

• Elicio Therapeutics, Inc.

• IO Biotech, Inc.

• MimiVax, Inc.

• BrightPath Biotherapeutics Co., Ltd.

• GreenPeptide Co., Ltd.

• OSE Immunotherapeutics SA

• Enterome SA

• Evaxion A/S

• Imugene Limited

• OncoTherapy Science, Inc.

• ISA Therapeutics / ISAbella Pharma

• Marker Therapeutics, Inc.

• Other Prominent Players